US Patent

US12239739 — Oral dosing of GLP-1 compounds

Method of Use · Assigned to Novo Nordisk AS · Expires 2034-05-02 · 8y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.

USPTO Abstract

The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.

Drugs covered by this patent

Ozempic (semaglutide) · Novo Nordisk

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-4388`	—	Ozempic
`U-4388`	—	Ozempic
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-2628`	—	Ozempic
`U-4388`	—	Ozempic
`U-2628`	—	Ozempic
`U-4388`	—	Ozempic

Patent Metadata

Patent number: US12239739
Jurisdiction: US
Classification: Method of Use
Expires: 2034-05-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Novo Nordisk AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.